News | January 16, 2009

SNM Cautions that Domestic Isotope Shortages Remain

January 16, 2009 - According to a report released Jan. 14, 2009, by the National Academy of Sciences (NAS), eliminating the highly enriched uranium process (HEU) — the primary source of medical isotopes in the U.S. — would be technically and economically feasible; however, the conversion to an alternative source will be years away, is likely to be more costly than the report estimates and will not alleviate the current ongoing shortages of medically necessary isotopes, according to the Society of Nuclear Medicine.

The NAS report, "Medical Isotope Production Without Highly Enriched Uranium," was mandated by Congress to examine the feasibility of conversion from HEU to a low enriched uranium (LEU) process and to make recommendations for how such a change may be made.

"The NAS report does not address concerns about isotope production that could have significant impact for patients requiring common diagnostic procedures," said Robert W. Atcher, Ph.D., M.B.A., president of SNM and chair of SNM's Isotope Availability Taskforce. "We are pleased by the prudent recommendations of the report and long-term view toward the potential conversion from HEU. However, the information used for developing the economic impact is suspect and the need for a reliable domestic isotope supply remains critical and is not addressed by this report, and continues to put patients at risk."

The majority of the U.S.' supply of medical radioisotopes is produced using HEU targets at reactors in Canada and Europe. In addition, there are currently no domestic producers of Molybdenum-99 (Mo-99)— from which Technectium-99m (Tc-99m) is derived—which is produced from HEU. The U.S. continues to rely on five facilities outside the country, which in the recent past have been unreliable due to their age and need for regular maintenance in addition to unscheduled outages due to safety and maintenance issues. Any disruption at these facilities causes significant delays to patients receiving nuclear medicine and molecular imaging procedures.

While the NAS report focuses on potential security concerns related to isotope production using HEU, there are significant regulatory, financial, environmental and patient issues linked with a conversion to LEU that must be taken into consideration before making any large-scale changes, said SNM.

"The report makes some prudent recommendations for a move away from HEU, such as involving the U.S. Food and Drug Administration early on in the conversion process," said Atcher. "Our concern is for our patients who benefit from molecular imaging and nuclear medicine tests for the detection and staging of cancer and other conditions. In addition, there is concern that the economic issues associated with the conversion to LEU production have not been adequately assessed nor addressed."

Continuing shutdowns due to maintenance work at the world's nuclear reactors that manufacture Mo-99 have increased the urgency of finding an alternative reliable domestic source for Mo-99.

For more information:

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...